Skip to Content
Merck
CN
All Photos(1)

Documents

SML0335

Sigma-Aldrich

Remacemide hydrochloride

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing

Synonym(s):
2-Amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, FPL 12924AA, PR 934-423A
Empirical Formula (Hill Notation):
C17H20N2O · HCl
CAS Number:
Molecular Weight:
304.81
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: >10 mg/mL

storage temp.

room temp

SMILES string

Cl.CC(Cc1ccccc1)(NC(=O)CN)c2ccccc2

InChI

1S/C17H20N2O.ClH/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14;/h2-11H,12-13,18H2,1H3,(H,19,20);1H

InChI key

HYQMIUSWZXGTCC-UHFFFAOYSA-N

Biochem/physiol Actions

Remacemide HCl is a low affinity NMDA antagonist with anticonvulsant properties. Remacemide also been shown to block voltage-dependent sodium channels.
Remacemide possesses neuroprotective and anti-epileptic actions. It supports reducing the frequency of seizures. Remacemide is also known to be a potential therapeutic for Huntington′s disease.

Features and Benefits

This compound is featured on the Glutamate Receptors (Ion Channel Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Eye Dam. 1

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M W Jones et al.
Seizure, 11(2), 104-113 (2002-04-12)
Remacemide hydrochloride is a low-affinity, non-competitive NMDA receptor channel blocker under investigation for the treatment of epilepsy. This double-blind, placebo-controlled, multicentre study assessed the safety and efficacy of adjunctive remacemide hydrochloride or placebo, in adult patients with refractory epilepsy who
Gillian P Bates et al.
Current opinion in neurology, 16(4), 465-470 (2003-07-19)
Research conducted over the past 10 years has uncovered molecular mechanisms that are likely to be important in the early stages of Huntington's disease pathogenesis. This review summarizes the resources and strategies that are in place in order to exploit
D Chadwick et al.
Seizure, 9(8), 544-550 (2001-02-13)
Forty patients (33 male, 7 female) with refractory epilepsy were randomized to receive ascending weekly doses of adjunctive remacemide hydrochloride in a b.i.d. or q.i.d. regimen, or placebo for up to 1 month. Assessments included routine physical examination and laboratory
Gabriele Schilling et al.
Experimental neurology, 187(1), 137-149 (2004-04-15)
The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological
Robert Małek et al.
Polish journal of pharmacology, 55(5), 691-698 (2004-01-06)
Epilepsy belongs to common diseases of the brain. It affects approximately 1% of the population. The aim of epilepsy therapy is to keep the patient free of seizures without interfering with normal brain function. Unfortunately, about 30% of all epilepsies

Articles

We offers many products related to ion channel family glutamate receptors for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service